Ocrelizumab
drugOn this page
Also known as 2H7Ocrelizumab component of ocrevus zunovoOcrelizumab-ocsqOcrevusPR-070769PR070769R-1594RG-1594
Summary
Ocrelizumab (CHEMBL2108041) is an approved antibody (ATC L04AG08) targeting MS4A1; indicated across 11 conditions including relapsing-remitting multiple sclerosis and chronic progressive multiple sclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AG08
- Targets: 1 (MS4A1)
- Indications: 11 conditions
- Clinical trials: 85
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108041 |
| Name | Ocrelizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AG08 |
Also known as: 2H7, Ocrelizumab, Ocrelizumab component of ocrevus zunovo, Ocrelizumab-ocsq, Ocrevus, PR-070769, PR070769, R-1594, RG-1594, OCRELIZUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| MS4A1 | CD20 (membrane-spanning 4-domains, subfamily A, member 1) | Binding | 9.08 | 0% | P11836 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): MS4A1.
Dominant GO biological processes
| GO term | Targets |
|---|---|
| store-operated calcium entry | 1 |
| humoral immune response | 1 |
| cell surface receptor signaling pathway | 1 |
| response to bacterium | 1 |
| B cell differentiation | 1 |
| B cell proliferation | 1 |
| B cell activation | 1 |
| B cell receptor signaling pathway | 1 |
| protein tetramerization | 1 |
| calcium ion import into cytosol | 1 |
| positive regulation of calcium ion import across plasma membrane | 1 |
Indications & clinical
Indications
11 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | 4 | MONDO:0005314 | EFO:0003929 |
| chronic progressive multiple sclerosis | 4 | MONDO:0005284 | EFO:0003840 |
| primary progressive multiple sclerosis | 4 | MONDO:0000451 | EFO:0008520 |
| multiple sclerosis | 4 | MONDO:0005301 | MONDO:0005301 |
| secondary progressive multiple sclerosis | 4 | MONDO:0000450 | EFO:0008522 |
| rheumatoid arthritis | 3 | MONDO:0008383 | EFO:0000685 |
| systemic lupus erythematosus | 3 | MONDO:0007915 | MONDO:0007915 |
| autoimmune disorder of the nervous system | 2 | MONDO:0002977 | MONDO:0020640 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| psychotic disorder | 1 | MONDO:0005485 | EFO:0005407 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 85.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 31 |
| Not specified | 24 |
| PHASE4 | 15 |
| PHASE2 | 8 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04387734 | PHASE4 | ACTIVE_NOT_RECRUITING | Effects of Ocrevus in Relapsing Multiple Sclerosis |
| NCT04466150 | PHASE4 | ACTIVE_NOT_RECRUITING | Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset |
| NCT05285891 | PHASE4 | RECRUITING | Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis |
| NCT06495593 | PHASE4 | ENROLLING_BY_INVITATION | Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis |
| NCT07389590 | PHASE4 | RECRUITING | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis |
| NCT07483450 | PHASE4 | RECRUITING | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis |
| NCT03589105 | PHASE4 | COMPLETED | A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting |
| NCT03853746 | PHASE4 | COMPLETED | Short-term B-cell Depletion in Relapsing Multiple Sclerosis |
| NCT04261790 | PHASE4 | COMPLETED | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis |
| NCT04377555 | PHASE4 | COMPLETED | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab |
| NCT04877457 | PHASE4 | TERMINATED | Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease. |
| NCT04998812 | PHASE4 | COMPLETED | A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy |
| NCT04998851 | PHASE4 | COMPLETED | A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab |
| NCT05208840 | PHASE4 | WITHDRAWN | A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis |
| NCT05296161 | PHASE4 | UNKNOWN | B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis |
| NCT03477500 | PHASE3 | ACTIVE_NOT_RECRUITING | Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) |
| NCT03523858 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis |
| NCT04035005 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis |
| NCT04544436 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) |
| NCT04544449 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis |
| NCT04548999 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) |
| NCT04578639 | PHASE3 | ACTIVE_NOT_RECRUITING | Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease |
| NCT04688788 | PHASE3 | ACTIVE_NOT_RECRUITING | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis |
| NCT05123703 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) |
| NCT05210621 | PHASE3 | ACTIVE_NOT_RECRUITING | LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB |
| NCT05269004 | PHASE3 | ACTIVE_NOT_RECRUITING | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis |
| NCT06675955 | PHASE3 | RECRUITING | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment |
| NCT06700343 | PHASE3 | RECRUITING | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) |
| NCT06846281 | PHASE3 | RECRUITING | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
| NCT07321093 | PHASE3 | RECRUITING | A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis |
| NCT00406419 | PHASE3 | TERMINATED | A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) |
| NCT00476996 | PHASE3 | TERMINATED | A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don’t Have a Response to Anti-TNF-α Therapy (SCRIPT) |
| NCT00485589 | PHASE3 | TERMINATED | A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM) |
| NCT00539838 | PHASE3 | TERMINATED | A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) |
| NCT00626197 | PHASE3 | TERMINATED | A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) |
| NCT00673920 | PHASE3 | TERMINATED | A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy |
| NCT01194570 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis |
| NCT01247324 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis |
| NCT01412333 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis |
| NCT02637856 | PHASE3 | COMPLETED | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).